kabutan

SanBio Company Limited(4592) Summary

4592
TSE Growth
SanBio Company Limited
1,832
JPY
-8
(-0.43%)
Jan 29, 3:30 pm JST
11.97
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
1,840.9
Jan 29, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
525
Yield
ー%
Margin Trading Ratio
159.54
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
1,822 JPY 11.89 USD
Previous Close Jan 28
1,840 JPY 12.05 USD
High Jan 29, 3:04 pm
1,845 JPY 12.05 USD
Low Jan 29, 9:09 am
1,784 JPY 11.65 USD
Volume
629,000
Trading Value
1.14B JPY 7.46M USD
VWAP
1813.47 JPY 11.86 USD
Minimum Trading Value
183,200 JPY 1,197 USD
Market Cap
0.14T JPY 0.94B USD
Number of Trades
2,056
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
8,286
1-Year High Oct 17, 2025
46,775
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 25,600 6,666,100 260.39
Jan 16, 2026 26,200 6,546,500 249.87
Jan 9, 2026 25,600 6,638,000 259.30
Dec 26, 2025 25,700 6,474,500 251.93
Dec 19, 2025 26,500 6,735,200 254.16
Company Profile
SanBio Company Limited is a biotech venture specializing in the development of regenerative cell therapies. Their products show promise for treating neurological disorders.
Sector
Pharmaceuticals
SanBio Company Limited is a biotech venture primarily focused on the research and development of regenerative cell medicines. Founded in the United States, the company later expanded into Japan. Their flagship product, SB623, is an allogeneic neural regenerative cell therapy targeting central nervous system disorders. The company has submitted a regulatory application in Japan for chronic traumatic brain injury and aims to expand its indications to include stroke and intracerebral hemorrhage. SanBio possesses proprietary cell culture and manufacturing technologies and has secured product supply rights. Given SB623's strong neuroprotective properties, the company is also exploring its potential in other conditions such as retinal diseases. SanBio employs a business model that combines in-house development with licensing agreements with partner companies. The company places a strong emphasis on securing intellectual property rights and is pursuing a business strategy with global expansion in mind.